Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Central South University
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01360866CT.gov Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mental Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Paroxetine (this asset) | Central South University | P3 | BB · 64 |
| Brexpiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | P3 | BBB |
| Provigil | Emory University | P4 | BB |
| Naltrexone | State University of New York - Upstate Medical University | P4 | BB |
| Galantamine Hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | BB |
| Gardasil 9 Vaccine | Eunice Dube | P4 | BB |
| Risperidone | Janssen Korea, Ltd., Korea | P3 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Olanzapine | AstraZeneca | P3 | BB |
+26 more in the Mental Disorder cohort
Other indications for Paroxetine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar Disorder | — | P4 | BBB · 74 |
| Depressive Disorder | — | P4 | BBB · 74 |
| Bipolar Depression | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Paroxetine in Mental Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/paroxetine-mental-disorder-119564
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →